TargED Biopharmaceuticals

📍 Utrecht, Netherlands🗓 Founded 2018👥 26 employees💰 Last funded Feb 2022
Pharmaceutical Manufacturing🌐 targedbiopharmaceuticals.com
Website LinkedIn
TargED started in September 2018 and is currently developing one biopharmaceutical product: MICROLYSE. MICROLYSE enzymatically breaks down blood clots in small blood vessels (i.e. the microvasculature), for which to date, no specific treatment exists. TargED pursues to receive market authorization for an orphan disease named Thrombotic Thrombocytopenic Purpura (TTP) that is characterized by life threatening attacks of microvascular thrombosis. However, MICROLYSE has the capacity to target all forms of microvascular thrombosis and could also be applied in early-stage macrovascular thrombosis as seen in heart attacks and stroke.
2
Total investors
0
Early stage
2
Mid stage
0
Late stage
2018
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Netherlands
2
Frequently asked questions
Who invested in TargED Biopharmaceuticals?
TargED Biopharmaceuticals has 2 investors on record on gritt.io, 2 mid-stage.
When did TargED Biopharmaceuticals last raise funding?
The most recent investment in TargED Biopharmaceuticals recorded on gritt.io was in February 2022.
When was TargED Biopharmaceuticals founded?
TargED Biopharmaceuticals was founded in 2018.
What industry is TargED Biopharmaceuticals in?
TargED Biopharmaceuticals operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is TargED Biopharmaceuticals based?
TargED Biopharmaceuticals is headquartered in Utrecht, Netherlands.